We are live on
!
Find out more
Calamos Advisors Portfolio holdings
AUM
$28.2B
1-Year Est. Return
21.78%
This Fund
S&P 500
This Quarter
Est. Return
+17.1%
1 Year Est. Return
+21.78%
3 Year Est. Return
+69.57%
5 Year Est. Return
+92%
10 Year Est. Return
+282.63%
AUM
$14.1B
AUM Growth
+$1.4B
(+11%)
Cap. Flow
-$4.28B
Cap. Flow
% of AUM
-30.25%
Top 10 Holdings %
Top 10 Hldgs %
20.4%
Holding
803
New
108
Increased
91
Reduced
295
Closed
98
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BSX.PRA
Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A
BSX.PRA
|
+$61M |
| 2 |
RTX Corp
RTX
|
+$38.2M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$15.5M |
| 4 |
Delta Air Lines
DAL
|
+$14.5M |
| 5 |
SWT
Stanley Black & Decker, Inc.
SWT
|
+$13.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$578M |
| 2 |
AGN
Allergan plc
AGN
|
+$67M |
| 3 |
BDXA
Becton, Dickinson and Company Depositary Shares, each Representing a 1/20th Interest in a Share of 6
BDXA
|
+$51.1M |
| 4 |
Alibaba
BABA
|
+$46.8M |
| 5 |
lululemon athletica
LULU
|
+$42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.91% |
| 2 | Healthcare | 8.15% |
| 3 | Consumer Discretionary | 7.49% |
| 4 | Financials | 7.2% |
| 5 | Communication Services | 5.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Carnival Corporation Ltd
CCL
$38.1B
| $973K | 0.01% |
59,260
-99,447
| -63% | -$1.49M |
|
477
Pegasystems
PEGA
$5.09B
| $969K | 0.01% |
19,146
-55,976
| -75% | -$2.43M |
|
|
TCO
478
DELISTED
Taubman Centers Inc.
TCO
| $950K | 0.01% |
+25,158
| New | +$1.03M |
|
479
Monolithic Power Systems
MPWR
$61.4B
| $943K | 0.01% |
+3,979
| New | +$805K |
|
480
PagerDuty
PD
$830M
| $927K | 0.01% |
+32,400
| New | +$781K |
|
|
XYZ
481
Block Inc
XYZ
$48.9B
| $897K | 0.01% |
8,550
+4,450
| +109% | +$341K |
|
482
Wendy's
WEN
$1.46B
| $871K | 0.01% |
+40,008
| New | +$795K |
|
|
AVDL
483
DELISTED
Avadel Pharmaceuticals
AVDL
| $862K | 0.01% |
+106,776
| New | +$941K |
|
484
Napco Security Technologies
NSSC
$1.3B
| $844K | 0.01% |
+72,180
| New | +$757K |
|
|
AZEK
485
DELISTED
The AZEK Co
AZEK
| $839K | 0.01% |
+26,329
| New | +$800K |
|
486
Schwab US Large- Cap ETF
SCHX
$70.3B
| $834K | 0.01% |
67,566
-10,368
| -13% | -$121K |
|
487
Simulations Plus
SLP
$371M
| $810K | 0.01% |
13,541
-9,647
| -42% | -$424K |
|
488
Insulet
PODD
$11.8B
| $809K | 0.01% |
4,164
-1,235
| -23% | -$236K |
|
|
RVNC
489
DELISTED
Revance Therapeutics, Inc.
RVNC
| $809K | 0.01% |
+33,126
| New | +$654K |
|
|
MASI
490
DELISTED
Masimo
MASI
| $799K | 0.01% |
+3,504
| New | +$769K |
|
491
CALL
Televisa
TV
$1.49B
| $757K | 0.01% |
+144,500
| New | +$800K |
|
492
Zscaler
ZS
$24.9B
| $756K | 0.01% |
+6,900
| New | +$573K |
|
|
SPLK
493
DELISTED
Splunk Inc
SPLK
| $752K | 0.01% |
+3,784
| New | +$599K |
|
494
Take-Two Interactive
TTWO
$46.1B
| $737K | 0.01% |
+5,277
| New | +$690K |
|
495
iShares Core US Aggregate Bond ETF
AGG
$138B
| $707K | 0.01% |
5,978
+727
| +14% | +$85.1K |
|
496
Paycom
PAYC
$7.88B
| $700K | ﹤0.01% |
+2,260
| New | +$602K |
|
497
Axsome Therapeutics
AXSM
$11.7B
| $695K | ﹤0.01% |
+8,446
| New | +$650K |
|
|
SGEN
498
DELISTED
Seagen Inc. Common Stock
SGEN
| $692K | ﹤0.01% |
+4,072
| New | +$607K |
|
499
Moderna
MRNA
$21.6B
| $665K | ﹤0.01% |
+10,364
| New | +$568K |
|
500
Chewy
CHWY
$9.54B
| $662K | ﹤0.01% |
+14,806
| New | +$646K |
|
Similar funds
PCH
N
TWC
FDCDDQ
NA
Calamos Advisors's Q2 2020 Portfolio in Review
As of Q2 2020, Calamos Advisors held 803 positions worth $14.1B, up 11% from $12.7B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Calamos Advisors withdrew a net $4.28B in Q2 2020, closing 98 positions and reducing 295 holdings. Its most notable exit was Allergan plc, an estimated $67M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Calamos Advisors opened a new position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A worth $59.7M.
- Calamos Advisors's largest Q2 2020 buy was Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A: 569,916 shares worth $59.7M.
- Calamos Advisors added most to RTX Corp in Q2 2020, an estimated $38.2M increase.
- Calamos Advisors's biggest Q2 2020 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $578M.
- Calamos Advisors fully exited Allergan plc in Q2 2020, selling an estimated $67M.
- Calamos Advisors's ten largest holdings make up 20% of its $14.1B portfolio in Q2 2020.
- Calamos Advisors opened 108 new positions and closed 98 in Q2 2020.
- Calamos Advisors's portfolio value rose 11% quarter-over-quarter to $14.1B.
Based on Calamos Advisors's 13F filing for Q2 2020, filed 27 Jul 2020.